4D Molecular Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:FDMT) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -50.91 M-69.13 M-86.69 M-75.79 M-134.59 M-109.08 M -129.45 M Cash from investing activities -1 M-172.68 M-17.05 M115.72 M-302.44 M-92.97 M -56.03 M Cash from financing activities 278.98 M118.09 M3.08 M156.83 M337.25 M112.96 M 124.44 M Free cash flow -51.91 M-69.13 M-86.69 M-75.79 M-134.59 M-109.62 M -129.35 M

News

4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:FDMT) 2026-01-19

RBC Capital reiterates Outperform rating on 4D Molecular stock at $32

Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)

BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Aimei Health Technology (NASDAQ:AFJK), Aura Biosciences (NASDAQ:AURA)

Avago and Oracle among market cap stock movers on Wednesday